<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601625</url>
  </required_header>
  <id_info>
    <org_study_id>D3461C00006</org_study_id>
    <nct_id>NCT02601625</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects</brief_title>
  <official_title>A Randomized, Phase 1, Placebo-controlled, Double-blind, Single-dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Subcutaneously and Intravenously Delivered Anifrolumab in Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the
      Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy
      subjects
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I placebo-controlled study to assess the pharmacokinetics, safety and
      tolerability of 2 doses of anifrolumab via the subcutaneous (SC) route of administration and
      1 dose of anifrolumab via intravenous (IV) route in healthy subjects
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2015</start_date>
  <completion_date type="Actual">May 25, 2016</completion_date>
  <primary_completion_date type="Actual">May 25, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab.</measure>
    <time_frame>On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days</time_frame>
    <description>To evaluate Cmax of anifrolumab after single administration of two doses subcutaneously and one dose intravenously.
Up to 13 blood samples were collected in total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Following Single Dose of Anifrolumab</measure>
    <time_frame>On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days</time_frame>
    <description>To evaluate AUC(0-t) of anifrolumab after single administration of two doses subcutaneously and one dose intravenously
Up to 13 blood samples were collected in total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) Following Single Dose of Anifrolumab</measure>
    <time_frame>On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days</time_frame>
    <description>To evaluate AUC of anifrolumab after single administration of two doses subcutaneously and one dose intravenously.
Up to 13 blood samples were collected in total.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>From screening to final follow-up visit, up to 16 weeks</time_frame>
    <description>To assess the safety and tolerability of single doses of anifrolumab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Summary of Local Injection Site Pain (SC Cohorts) Assessed in Participants</measure>
    <time_frame>Immediately after dosing, at 10, 20 minutes and 1 hour after injection</time_frame>
    <description>Local injection site pain was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = &quot;no pain&quot; to 100 = &quot;worst imaginable pain&quot;). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Summary of Local Injection Site Pruritus (SC Cohorts) Assessed in Participants</measure>
    <time_frame>Immediately after dosing, at 10, 20 minutes and 1 hour after injection</time_frame>
    <description>Local injection site pruritus was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = &quot;no itching&quot; to 100 = &quot;worst imaginable itching&quot;). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Summary of Erythema Injection Site Reaction (SC Cohorts) Assessed in Participants</measure>
    <time_frame>Immediately after dosing, at 10, 20 minutes and 1 hour after injection</time_frame>
    <description>Erythema was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Summary of the Induration Injection Site Reaction (SC Cohorts) Assessed in Participants</measure>
    <time_frame>Immediately after dosing, at 10, 20 minutes and 1 hour after injection</time_frame>
    <description>Induration was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Immunogenicity of Anifrolumab IV Infusions and SC Injections by the Measurement of Anti-drug Antibody (ADA).</measure>
    <time_frame>Pre-dose and at Days 5 and Day 29, up to 85 days</time_frame>
    <description>Immunogenicity was assessed in all groups by the presence or absence of ADA, which was determined in serum samples using validated bioanalytical methods. The reported results are based on the confirmatory assay (positive/negative) of the ADA. The number of participants with positive, negative and missing results are reported for each time point using the safety analysis set.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Safety</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Anifrolumab 300 mg SC injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg single dose anifrolumab delivered as 2 separate 1 mL SC injections administered serially</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anifrolumab 300 mg IV infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg single dose anifrolumab delivered as an IV infusion over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anifrolumab 600 mg SC infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>600 mg single dose anifrolumab or placebo delivered as 4 mL SC by infusion pump</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 300 mg SC injections</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 300 mg IV infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mg single dose placebo delivered as an IV infusion over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo 600mg SC infusion</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>600 mg single dose placebo delivered as 4 mL SC by infusion pump</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab SC injection (300mg)</intervention_name>
    <description>300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1</description>
    <arm_group_label>Anifrolumab 300 mg SC injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab IV infusion (300mg)</intervention_name>
    <description>300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1</description>
    <arm_group_label>Anifrolumab 300 mg IV infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab SC infusion (600mg)</intervention_name>
    <description>600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1</description>
    <arm_group_label>Anifrolumab 600 mg SC infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab placebo SC injection (300mg)</intervention_name>
    <description>300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1</description>
    <arm_group_label>Placebo 300 mg SC injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab placebo IV infusion (300mg)</intervention_name>
    <description>600mg of placebo delivered as an IV infusion over 30 minutes on Day 1</description>
    <arm_group_label>Placebo 300 mg IV infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anifrolumab placebo SC infusion (600mg)</intervention_name>
    <description>600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1</description>
    <arm_group_label>Placebo 600mg SC infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated, written informed consent prior to any study specific
             procedures.

          2. Healthy male and/or female subjects aged 18 - 55 years.

          3. Females must have a negative pregnancy test at screening.

          4. Females with an intact cervix must have documentation of a Pap smear with no
             documented malignancy.

          5. Have a body mass index (BMI) between 18 and 32 kg/m2, inclusive, and weigh at least 50
             kg.

          6. Must have adequate abdominal adipose tissue for SC injection.

          7. No history of latent or active TB prior to screening.

          8. A chest radiograph with no evidence of current active infection or old active TB,
             malignancy, or clinically significant abnormalities within 6 months prior to
             screening.

        Exclusion Criteria:

          1. History of any clinically significant disease or disorder which may put the subject at
             risk .

          2. History or presence of hepatic or renal disease.

          3. Any clinically significant illness, medical/surgical procedure, or trauma within 8
             weeks of participation .

          4. Any clinically significant chronic or recent infection requiring hospitalization or
             treatment with anti-infectives.

          5. History of cancer, apart from squamous or basal cell carcinoma of the skin.

          6. Any clinically significant lab, vital sign or ECG abnormalities as judged by the
             investigator.

          7. Known history of a primary immunodeficiency,HIV splenectomy or an underlying
             condition.

          8. Any positive result on screening for hepatitis B, hepatitis C or HIV antibody.

          9. History of drug abuse within 1 year of participation.

         10. Has received another new chemical entity (defined as a compound which has not been
             approved for marketing) within 4 weeks or 5 half-lives prior to participation.

         11. Previous receipt of:

               -  Anifrolumab;

               -  B cell-depleting therapy (including but not limited to epratuzumab, ocrelizumab,
                  or rituximab) ≤ 52 weeks prior to screening.

         12. History of allergy/hypersensitivity to drugs with a similar chemical structure or
             class to anifrolumab or to any human gamma globulin therapy.

         13. Any live or attenuated vaccine within 8 weeks prior to participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Goldwater, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL Early Phase Clinical Unit, Baltimore, United States of America</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=3872&amp;filename=d3461c00006-revised-study-protocol-1_REDACTED.PDF</url>
    <description>d3461c00006-revised-study-protocol-1_REDACTED</description>
  </link>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <results_first_submitted>May 23, 2017</results_first_submitted>
  <results_first_submitted_qc>February 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tolerability</keyword>
  <keyword>Anifrolumab</keyword>
  <keyword>Subcutaneous injection</keyword>
  <keyword>Intravenous infusion</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted at the PAREXEL Early Phase Clinical Unit Baltimore, 3001 S. Hanover St.
Baltimore, MD 21225 United States of America</recruitment_details>
      <pre_assignment_details>All eligible participants underwent a screening period of a maximum of 28 days. During the treatment period all participants were asked to be the residents at the study site prior to the evening meal the night before dosing with anifrolumab or placebo (Day -1) until at least 48 hours after dosing; and were then discharged on the morning of Day 3.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Anifrolumab 300 mg SC Injections</title>
          <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
        </group>
        <group group_id="P2">
          <title>Anifrolumab 300 mg IV Infusion</title>
          <description>Participants received single dose of anifrolumab 300 mg delivered as an intravenous (IV) infusion over 30 minutes on Day 1</description>
        </group>
        <group group_id="P3">
          <title>Anifrolumab 600 mg SC Infusion</title>
          <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
        </group>
        <group group_id="P4">
          <title>Pooled Placebo</title>
          <description>Randomized participants received Anifrolumab matching placebo.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Thirty healthy male and female subjects were included in this study, 6 subjects per anifrolumab treatment (300 mg anifrolumab SC, 300 mg anifrolumab IV, 600 mg anifrolumab SC) and 12 subjects for placebo treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Anifrolumab 300 mg SC Injections</title>
          <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
        </group>
        <group group_id="B2">
          <title>Anifrolumab 300 mg IV Infusion</title>
          <description>Participants received single dose of anifrolumab 300 mg delivered as an intravenous (IV) infusion over 30 minutes on Day 1</description>
        </group>
        <group group_id="B3">
          <title>Anifrolumab 600 mg SC Infusion</title>
          <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
        </group>
        <group group_id="B4">
          <title>Pooled Placebo</title>
          <description>Randomized participants received Anifrolumab matching placebo.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.5" spread="6.89"/>
                    <measurement group_id="B2" value="29.7" spread="7.97"/>
                    <measurement group_id="B3" value="26.3" spread="6.65"/>
                    <measurement group_id="B4" value="38.4" spread="12.26"/>
                    <measurement group_id="B5" value="32.1" spread="10.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Count of participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab.</title>
        <description>To evaluate Cmax of anifrolumab after single administration of two doses subcutaneously and one dose intravenously.
Up to 13 blood samples were collected in total.</description>
        <time_frame>On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days</time_frame>
        <population>The pharmacokinetic (PK) analysis set consisted of all participants in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations that had an impact on the analysis of the PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 300 mg SC Injections</title>
            <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg IV Infusion</title>
            <description>Participants received single dose of anifrolumab 300 mg delivered as an intravenous (IV) infusion over 30 minutes on Day 1</description>
          </group>
          <group group_id="O3">
            <title>Anifrolumab 600 mg SC Infusion</title>
            <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Observed Maximum Serum Concentration (Cmax) Following Single Dose of Anifrolumab.</title>
          <description>To evaluate Cmax of anifrolumab after single administration of two doses subcutaneously and one dose intravenously.
Up to 13 blood samples were collected in total.</description>
          <population>The pharmacokinetic (PK) analysis set consisted of all participants in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations that had an impact on the analysis of the PK data</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.22" spread="11.63"/>
                    <measurement group_id="O2" value="82.44" spread="13.16"/>
                    <measurement group_id="O3" value="63.86" spread="20.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Following Single Dose of Anifrolumab</title>
        <description>To evaluate AUC(0-t) of anifrolumab after single administration of two doses subcutaneously and one dose intravenously
Up to 13 blood samples were collected in total.</description>
        <time_frame>On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days</time_frame>
        <population>The PK analysis set consisted of all participants in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations that had an impact on the analysis of the PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 300 mg SC Injections</title>
            <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg IV Infusion</title>
            <description>Participants received single dose of anifrolumab 300 mg delivered as an intravenous (IV) infusion over 30 minutes on Day 1</description>
          </group>
          <group group_id="O3">
            <title>Anifrolumab 600 mg SC Infusion</title>
            <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Serum Concentration-time Curve From Time Zero to Time of Last Quantifiable Concentration (AUC0-t) Following Single Dose of Anifrolumab</title>
          <description>To evaluate AUC(0-t) of anifrolumab after single administration of two doses subcutaneously and one dose intravenously
Up to 13 blood samples were collected in total.</description>
          <population>The PK analysis set consisted of all participants in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations that had an impact on the analysis of the PK data</population>
          <units>day*μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="769.1" spread="336.9"/>
                    <measurement group_id="O2" value="902.9" spread="175.8"/>
                    <measurement group_id="O3" value="1639" spread="557.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) Following Single Dose of Anifrolumab</title>
        <description>To evaluate AUC of anifrolumab after single administration of two doses subcutaneously and one dose intravenously.
Up to 13 blood samples were collected in total.</description>
        <time_frame>On Day 1 pre-dose and at 5 minutes (IV cohort only), 24 and 48 hours post-dose and at each follow-up visit, up to 85 days</time_frame>
        <population>The PK analysis set consisted of all participants in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations that had an impact on the analysis of the PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 300 mg SC Injections</title>
            <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg IV Infusion</title>
            <description>Participants received single dose of anifrolumab 300 mg delivered as an intravenous (IV) infusion over 30 minutes on Day 1</description>
          </group>
          <group group_id="O3">
            <title>Anifrolumab 600 mg SC Infusion</title>
            <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under Serum Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC) Following Single Dose of Anifrolumab</title>
          <description>To evaluate AUC of anifrolumab after single administration of two doses subcutaneously and one dose intravenously.
Up to 13 blood samples were collected in total.</description>
          <population>The PK analysis set consisted of all participants in the safety analysis set for whom at least 1 of the primary PK parameters could be calculated, and who had no major protocol deviations that had an impact on the analysis of the PK data</population>
          <units>day*μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="784.6" spread="330.6"/>
                    <measurement group_id="O2" value="906.5" spread="174.9"/>
                    <measurement group_id="O3" value="1828" spread="679.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Number of Participants With Adverse Events (AEs)</title>
        <description>To assess the safety and tolerability of single doses of anifrolumab</description>
        <time_frame>From screening to final follow-up visit, up to 16 weeks</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of investigational medicinal product (IMP) (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 300 mg SC Injections</title>
            <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg IV Infusion</title>
            <description>Participants received single dose of anifrolumab 300 mg delivered as an intravenous (IV) infusion over 30 minutes on Day 1</description>
          </group>
          <group group_id="O3">
            <title>Anifrolumab 600 mg SC Infusion</title>
            <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
          </group>
          <group group_id="O4">
            <title>Pooled Placebo</title>
            <description>Randomized participants received Anifrolumab matching placebo.</description>
          </group>
          <group group_id="O5">
            <title>Placebo 300 mg Anifrolumab SC</title>
            <description>Participants received a single dose of placebo 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O6">
            <title>Placebo 600 mg Anifrolumab SC</title>
            <description>Participants received single dose of placebo 600 mg delivered as 4 mL SC by infusion pump.</description>
          </group>
          <group group_id="O7">
            <title>Placebo 300 mg Anifrolumab IV</title>
            <description>Participants received Single dose of placebo 300 mg delivered as an IV infusion over 30 minutes.</description>
          </group>
          <group group_id="O8">
            <title>All Anifrolumab Participants</title>
            <description>Overall number of participants who received anifrolumab therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Number of Participants With Adverse Events (AEs)</title>
          <description>To assess the safety and tolerability of single doses of anifrolumab</description>
          <population>The safety analysis set included all participants who received at least 1 dose of investigational medicinal product (IMP) (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Summary of Local Injection Site Pain (SC Cohorts) Assessed in Participants</title>
        <description>Local injection site pain was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = &quot;no pain&quot; to 100 = &quot;worst imaginable pain&quot;). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.</description>
        <time_frame>Immediately after dosing, at 10, 20 minutes and 1 hour after injection</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of IMP (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 300 mg SC Injections</title>
            <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 600 mg SC Infusion</title>
            <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
          </group>
          <group group_id="O3">
            <title>Placebo 300 mg Anifrolumab SC</title>
            <description>Participants received a single dose of placebo 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo 600 mg Anifrolumab SC</title>
            <description>Participants received single dose of placebo 600 mg delivered as 4 mL SC by infusion pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Summary of Local Injection Site Pain (SC Cohorts) Assessed in Participants</title>
          <description>Local injection site pain was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = &quot;no pain&quot; to 100 = &quot;worst imaginable pain&quot;). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of IMP (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immediately after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.21"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="8.0" spread="13.69"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.63"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.5" spread="1.00"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.42"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.4" spread="0.75"/>
                    <measurement group_id="O4" value="0.3" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.41"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.3" spread="0.50"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Summary of Local Injection Site Pruritus (SC Cohorts) Assessed in Participants</title>
        <description>Local injection site pruritus was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = &quot;no itching&quot; to 100 = &quot;worst imaginable itching&quot;). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.</description>
        <time_frame>Immediately after dosing, at 10, 20 minutes and 1 hour after injection</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of IMP (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 300 mg SC Injections</title>
            <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 600 mg SC Infusion</title>
            <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
          </group>
          <group group_id="O3">
            <title>Placebo 300 mg Anifrolumab SC</title>
            <description>Participants received a single dose of placebo 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo 600 mg Anifrolumab SC</title>
            <description>Participants received single dose of placebo 600 mg delivered as 4 mL SC by infusion pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Summary of Local Injection Site Pruritus (SC Cohorts) Assessed in Participants</title>
          <description>Local injection site pruritus was assessed using a 100 mm participant rated Visual Analog Scale (VAS 0mm - 100mm ungraduated scale, where 0 = &quot;no itching&quot; to 100 = &quot;worst imaginable itching&quot;). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average VAS score (0mm-100mm) of the two injection sites were reported.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of IMP (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immediately after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.60"/>
                    <measurement group_id="O2" value="14.0" spread="20.29"/>
                    <measurement group_id="O3" value="1.3" spread="1.66"/>
                    <measurement group_id="O4" value="0.8" spread="0.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 min after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.21"/>
                    <measurement group_id="O2" value="6.3" spread="14.56"/>
                    <measurement group_id="O3" value="0.6" spread="1.25"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 min after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.52"/>
                    <measurement group_id="O2" value="1.5" spread="3.67"/>
                    <measurement group_id="O3" value="0.5" spread="1.00"/>
                    <measurement group_id="O4" value="0.3" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.20"/>
                    <measurement group_id="O2" value="0.0" spread="0.00"/>
                    <measurement group_id="O3" value="0.4" spread="0.75"/>
                    <measurement group_id="O4" value="0.0" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Summary of Erythema Injection Site Reaction (SC Cohorts) Assessed in Participants</title>
        <description>Erythema was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.</description>
        <time_frame>Immediately after dosing, at 10, 20 minutes and 1 hour after injection</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of IMP (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 300 mg SC Injections</title>
            <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 600 mg SC Infusion</title>
            <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
          </group>
          <group group_id="O3">
            <title>Placebo 300mg SC Injection</title>
            <description>Participants received 300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo 600 mg SC Injection</title>
            <description>Participants received placebo 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Summary of Erythema Injection Site Reaction (SC Cohorts) Assessed in Participants</title>
          <description>Erythema was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of IMP (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immediately after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.42"/>
                    <measurement group_id="O2" value="17.0" spread="19.75"/>
                    <measurement group_id="O3" value="11.5" spread="14.62"/>
                    <measurement group_id="O4" value="20.0" spread="13.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minutes after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="4.18"/>
                    <measurement group_id="O2" value="17.5" spread="21.39"/>
                    <measurement group_id="O3" value="5.1" spread="9.59"/>
                    <measurement group_id="O4" value="18.0" spread="14.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minute after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" spread="4.14"/>
                    <measurement group_id="O2" value="16.6" spread="20.81"/>
                    <measurement group_id="O3" value="5.5" spread="9.11"/>
                    <measurement group_id="O4" value="26.0" spread="18.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.52"/>
                    <measurement group_id="O2" value="2.5" spread="6.12"/>
                    <measurement group_id="O3" value="0.3" spread="0.50"/>
                    <measurement group_id="O4" value="10.0" spread="14.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Immunogenicity of Anifrolumab IV Infusions and SC Injections by the Measurement of Anti-drug Antibody (ADA).</title>
        <description>Immunogenicity was assessed in all groups by the presence or absence of ADA, which was determined in serum samples using validated bioanalytical methods. The reported results are based on the confirmatory assay (positive/negative) of the ADA. The number of participants with positive, negative and missing results are reported for each time point using the safety analysis set.</description>
        <time_frame>Pre-dose and at Days 5 and Day 29, up to 85 days</time_frame>
        <population>The safety analysis set included all subjects who received at least 1 dose of IMP (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 300 mg SC Injections</title>
            <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 300 mg IV Infusion</title>
            <description>Participants received single dose of anifrolumab 300 mg delivered as an intravenous (IV) infusion over 30 minutes on Day 1</description>
          </group>
          <group group_id="O3">
            <title>Anifrolumab 600 mg SC Infusion</title>
            <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
          </group>
          <group group_id="O4">
            <title>Pooled Placebo</title>
            <description>Randomized participants received Anifrolumab matching placebo.</description>
          </group>
          <group group_id="O5">
            <title>All Subjects</title>
            <description>Overall participants.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Immunogenicity of Anifrolumab IV Infusions and SC Injections by the Measurement of Anti-drug Antibody (ADA).</title>
          <description>Immunogenicity was assessed in all groups by the presence or absence of ADA, which was determined in serum samples using validated bioanalytical methods. The reported results are based on the confirmatory assay (positive/negative) of the ADA. The number of participants with positive, negative and missing results are reported for each time point using the safety analysis set.</description>
          <population>The safety analysis set included all subjects who received at least 1 dose of IMP (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1, pre-dose (positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, pre-dose (negative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1, pre-dose (missing)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (negative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5 (missing)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (negative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29 (missing)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (positive)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (negative)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="11"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85 (missing)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Safety: Summary of the Induration Injection Site Reaction (SC Cohorts) Assessed in Participants</title>
        <description>Induration was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.</description>
        <time_frame>Immediately after dosing, at 10, 20 minutes and 1 hour after injection</time_frame>
        <population>The safety analysis set included all participants who received at least 1 dose of IMP (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
        <group_list>
          <group group_id="O1">
            <title>Anifrolumab 300 mg SC Injections</title>
            <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Anifrolumab 600 mg SC Infusion</title>
            <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
          </group>
          <group group_id="O3">
            <title>Placebo 300mg SC Injection</title>
            <description>Participants received 300 mg single dose placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1.</description>
          </group>
          <group group_id="O4">
            <title>Placebo 600 mg Anifrolumab SC</title>
            <description>Participants received single dose of placebo 600 mg delivered as 4 mL SC by infusion pump.</description>
          </group>
        </group_list>
        <measure>
          <title>Safety: Summary of the Induration Injection Site Reaction (SC Cohorts) Assessed in Participants</title>
          <description>Induration was measured as the largest diameter across the needle site on the skin in millimetres (mm). This assessment was taken for only those participants in subcutaneously dosed treatment groups; 600 mg SC and 300 mg SC, anifrolumab and placebo. For the 300 mg SC anifrolumab and 300 mg SC placebo groups which received two simultaneous injections, the average of the two injection site diameters (mm) were reported.</description>
          <population>The safety analysis set included all participants who received at least 1 dose of IMP (anifrolumab or placebo) and for whom any safety post-dose data were available.</population>
          <units>Millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Immediately after dosing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="10.21"/>
                    <measurement group_id="O2" value="22.5" spread="13.69"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="12.5" spread="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>10 minutes after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="2.04"/>
                    <measurement group_id="O2" value="17.3" spread="12.39"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="16.5" spread="19.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>20 minute after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.20"/>
                    <measurement group_id="O2" value="14.1" spread="11.41"/>
                    <measurement group_id="O3" value="0.1" spread="0.25"/>
                    <measurement group_id="O4" value="8.0" spread="16.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 hour after injection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.00"/>
                    <measurement group_id="O2" value="11.7" spread="13.29"/>
                    <measurement group_id="O3" value="0.0" spread="0.00"/>
                    <measurement group_id="O4" value="12.5" spread="25.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From screening to final follow-up visit, up to 16 weeks</time_frame>
      <desc>An adverse event (AE) is any undesirable medical condition or the deterioration of a pre existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Anifrolumab 300 mg SC Injections</title>
          <description>Participants received a single dose of anifrolumab 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
        </group>
        <group group_id="E2">
          <title>Anifrolumab 300 mg IV Infusion</title>
          <description>Participants received single dose of anifrolumab 300 mg delivered as an intravenous (IV) infusion over 30 minutes on Day 1</description>
        </group>
        <group group_id="E3">
          <title>Placebo 300 mg Anifrolumab SC</title>
          <description>Participants received a single dose of placebo 300 mg delivered as 2 separate 1 mL subcutaneous (SC) injections administered serially on Day 1.</description>
        </group>
        <group group_id="E4">
          <title>Placebo 300 mg IV Infusion</title>
          <description>Participants received 300 mg single dose placebo delivered as an IV infusion over 30 minutes on Day 1.</description>
        </group>
        <group group_id="E5">
          <title>Placebo 600 mg Anifrolumab (SC)</title>
          <description>Participants received 600 mg single dose placebo delivered as 4 mL SC by infusion pump on Day 1.</description>
        </group>
        <group group_id="E6">
          <title>Anifrolumab 600 mg SC Infusion</title>
          <description>Participants received single dose of anifrolumab 600 mg delivered as 4 mL SC by infusion pump on Day 1</description>
        </group>
        <group group_id="E7">
          <title>Pooled Placebo</title>
          <description>Randomized participants received Anifrolumab matching placebo.</description>
        </group>
        <group group_id="E8">
          <title>All Anifrolumab Subjects</title>
          <description>Overall number of participants who received anifrolumab therapy</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA Version 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Infusion site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All of the study information and data collected during the study are confidential and the property of AstraZeneca. After completion of the study, the investigator may prepare a joint publication with AstraZeneca. The investigator must undertake not to submit any part of the individual data from this study for publication without prior consent of AstraZeneca at a mutually agreed time.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anifrolumab Global Clinical Leader</name_or_title>
      <organization>AstraZeneca AB</organization>
      <phone>+46317761000</phone>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

